San Diego, USA / Shanghai, China, May 9th, 2023，ABM Therapeutics, a clinical-stage biotech company with a focus on treating primary brain cancers and other solid tumors with brain metastases today announced that the company will attend American Society of Clinical Oncology (ASCO) annual Meeting in Chicago on June 2–6, 2023.

The American Society of Clinical Oncology (ASCO) is the largest and leading global oncology conference. The clinical research progress of the innovative ABM-1310 developed by ABM Therapeutics will be presented at the Developmental Therapeutics poster session. Our team looks forward to in-depth communication with oncology experts, business partners and investors from all over the world.

 

From ASCO website

 

Title: A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with BRAFv600-mutated solid tumors.
Poster Session: Developmental Therapeutics — Molecularly Targeted Agents and Tumor Biology
Abstract number: 3098   

Poster number: 296 Hall A

Time: 9am-12am, June 3rd, 2023

ABM-1310 is a novel small-molecule BRAF inhibitor with high water solubility, cell permeability, and blood-brain barrier penetration as demonstrated in preclinical studies. In this poster, we report the clinical trial progress and preliminary results from a first-in-patient phase 1 study of ABM-1310.

 

About ABM Therapeutics
ABM Therapeutics, a clinical-stage biopharmaceutical company with a mission to focus on the small molecule research and development of novel drugs for the treatment of cancer, and on brain cancer and cancer metastases. ABM has been building its broad and robust proprietary pipeline to construct a brain medicine R&D platform through collaboration with CROs. ABM’s pipeline includes several programs in various stages of discovery and development, most of which have improved brain permeability to address the unmet needs of treating cancers and metastases in the brain.